Allergan
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Allergan sits in the top decile of US sponsors by registered trial count (#114 of 15,742 sponsors by registered trial count).
Allergan: 314 sponsored US clinical trials, none currently recruiting.
Allergan sponsors 314 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 278 completed. 142 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ocular Hypertension, with 9 trials.
Top-decile sponsor footprint
Allergan ranks in the top decile of sponsors by registered trial count (#114 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
278 of 313 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
314 total, page 4 of 7
A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction
NCT01633788
BOTOX® Treatment in Pediatric Upper Limb Spasticity
NCT01603602
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
NCT01600716
A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery
NCT01605942
BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
NCT01575054
Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale
NCT01636765
Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®
NCT01608672
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
NCT01579084
Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema
NCT01492400
Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)
NCT01540370
A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension
NCT01525173
Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy Women
NCT01518270
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
NCT01516892
Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis
NCT01475253
Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease
NCT01459588
Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence
NCT01448525
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
NCT01470118
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
NCT01397409
A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma
NCT01426113
Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale
NCT01412086
Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)
NCT01411696
Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines
NCT01391312
Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss
NCT01325350
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
NCT01325337
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
NCT01224015
Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT01291108
Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
NCT01319318
Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT01253902
Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy
NCT01229410
An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes
NCT01623479
Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye
NCT01319773
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines
NCT01189747
Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
NCT01157377
Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
NCT01189279
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
NCT01215786
Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
NCT01177098
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
NCT01157364
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
NCT01189760
Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augmentation
NCT01197495
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
NCT01107392
QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo
NCT01191723
A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
NCT01231334
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
NCT01178827
Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
NCT01122511
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
NCT01023841
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
NCT01110499
Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium
NCT01109056
A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia
NCT01129531
Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
NCT01099774
Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye
NCT01161771
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 85 |
| Phase 3 | 91 |
| Phase 4 | 51 |
Therapeutic Areas
How the Allergan archive is shaped
314 indexed studies, none listed as recruiting (0% open); 278 completed (89%).
Phase mix: 142 late (III/IV) vs 114 early (I/II) (balanced across stages).
Top condition: Ocular Hypertension (9 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Allergan: archived-pipeline peers nationwide
Peers matched on 314 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Allergan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 314 archived trials
- University of Arkansas · 318 trials · 12% recruiting
- Rush University Medical Center · 320 trials · 17% recruiting
- Celgene · 308 trials · 4% recruiting
- Jonsson Comprehensive Cancer Center · 321 trials · 19% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Allergan page
314 registered trials is a research-attention snapshot, not an endorsement of Allergan or any single study.
- None of Allergan's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Ocular Hypertension is the condition Allergan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ocular Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Allergan pipeline card: 314 registered trials from official public datasets.Report a data error.